KNTE News and Press, Kinnate Biopharma Inc. From 06/11/23

2023-06-11 09:51:51 ET Summary Shares of precision oncology concern Kinnate Biopharma Inc. (KNTE) have crashed 93% from their all-time high as long overdue data from a Phase 1 study failed to impress. The company is advancing a couple of early-stage compounds but has hit some bump...

2023-06-01 08:45:42 ET Palm Beach, FL – June 1, 2023 – FinancialNewsMedia.com News Commentary – Neurofibromatosis is a genetic condition that disrupts the cell growth in your nervous system, causing formation of tumors on nerve tissue. These formed tumor...

2023-05-21 10:56:57 ET Summary KNTE targets these two less-targeted BRAF classes. They have some clinical data, but data is not very strong. They have more cash than their market cap. Kinnate Biopharma ( KNTE ) develops small molecule kinase inhibitors to treat g...

2023-05-11 17:03:52 ET Kinnate Biopharma press release ( NASDAQ: KNTE ): Q1 GAAP EPS of -$0.73 beats by $0.01 . For further details see: Kinnate Biopharma GAAP EPS of -$0.73 beats by $0.01

Presented positive monotherapy dose escalation data for exarafenib, an investigational pan-RAF inhibitor, at the 2023 AACR Annual Meeting Provided update on ongoing exarafenib monotherapy dose expansion; data-informed strategy prioritizes enrollment in BRAF Class II-driven solid tumor...

2023-05-03 13:00:53 ET If you’re looking for the best penny stocks to buy, chances are that you’re looking for potential catalysts. This might come in the form of news headlines, social sentiment, speculation, or a mix of different catalysts. One that has stood out for inv...

2023-04-18 12:50:32 ET Gainers: BELLUS Health ( BLU ) +98% . Dermata Therapeutics ( DRMA ) +68% . Gamida Cell ( GMDA ) +53% . Allarity Therapeutics ( ALLR ) +45% . Esports Entertainment Group ( GMBL ) +35% . Altamira Therapeu...

2023-04-17 14:59:28 ET Kinnate Biopharma ( NASDAQ: KNTE ) said that the ~$231M in cash, cash equivalents, and investments on hand is enough to fund operations through early 2025. The company said it is also advancing two additional candidates into the clinic: KIN-7136 for ...

KIN-7136, a next generation brain-penetrant MEK inhibitor for MAPK-driven advanced adult solid tumors, is expected to enter the clinic in the second half of 2023 KIN-8741, a highly selective c-MET inhibitor designed to cover acquired resistance in non-small cell lung cancer and other ad...

Exarafenib was well-tolerated at substantial monotherapy exposures; only 3% (n=2/60) of patients discontinued therapy due to treatment-related adverse events Breadth of responses observed across tumor types and BRAF or NRAS alterations with a total of 8 partial responses in the monoth...